Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma.

Keda ShaoXiaohong ZengYue HaoYanhua WangChunwei XuZhengbo Song

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)

Rechallenge immunotherapy has poor efficacy in immunotolerant TC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors